Related Experiment Videos
Percutaneous hepatic infarction therapy for hepatocellular carcinoma
M Imamura1, Y Shiratori, S Sato
1Department of Internal Medicine (II), University of Tokyo, Japan.
AJR. American Journal of Roentgenology
|October 8, 1998
Summary
Ethanol injection into tumor-feeding vessels induced hepatic infarction for hepatocellular carcinoma. This percutaneous hepatic infarction therapy shows promise for treating large tumors.
Area of Science:
- Interventional Radiology
- Hepatobiliary Oncology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer with significant global impact.
- Treatment options for large HCC can be limited, necessitating innovative therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy of percutaneous ethanol injection into afferent vessels for inducing hepatic infarction in HCC.
- To assess the potential of this technique as a novel treatment modality for large HCC.
Main Methods:
- Percutaneous ethanol injection was performed targeting small vessels supplying HCC tumor nodules.
- The procedure aimed to induce localized hepatic infarction within the tumor areas.
Main Results:
- Successful induction of hepatic infarction in the targeted tumor regions.
- Demonstrated feasibility of the percutaneous approach for delivering ethanol to tumor vasculature.
Conclusions:
- Percutaneous hepatic infarction therapy (PHIT) is a promising new treatment for large hepatocellular carcinoma.
- PHIT offers a minimally invasive option for managing advanced HCC, potentially improving patient outcomes.